GDF15 and portal hypertension: Thus, we decided to measure GDF‐15 in patients with cirrhosis to investigate (i) its association with key liver disease‐driving mechanisms and portal hypertension, (ii) its relationship with platelet function, and (iii) its prognostic value for hepatic decompensation, liver‐related death and all‐cause mortality.